CAPR
$31.19
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Recent News
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance
Capricor Therapeutics Inc. (NASDAQ:CAPR) is one of the best hot stocks to buy according to analysts. On March 12, Capricor Therapeutics presented new late-breaking data from its Phase 3 HOPE-3 clinical trial at the 2026 MDA Conference, highlighting the benefits of Deramiocel for Duchenne muscular dystrophy. Cardiac MRI results showed a reduction in myocardial fibrosis […]
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge?
If you are wondering whether Capricor Therapeutics at around US$30.50 is priced for its potential or already running ahead of itself, you are not alone. The stock has posted returns of 9.3% over the last 7 days, 26.0% over 30 days and 7.7% year to date, with a 1 year gain of 130.5% and a very large 3 year return that is more than 7x. This naturally raises questions about what is already baked into the price. Recent news around Capricor Therapeutics has centered on its progress in the...
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ...
Capricor Therapeutics Inc (CAPR) advances with FDA acceptance for Jeremiasel, but faces revenue decline and increased expenses.
Capricor (CAPR) Q4 2025 Earnings Call Transcript
Linda Marbán: Good afternoon, everyone, and thank you for joining us on Capricor Therapeutics, Inc.’s quarterly conference call. For our investors, collaborators, the team here at Capricor Therapeutics, Inc., and especially the Duchenne muscular dystrophy patient community, thank you for your continued support and belief in our mission. As we announced earlier this week, we were very pleased to report that the U.S. Food and Drug Administration has stated that our response to our complete response letter is complete and has therefore been accepted, our previously submitted biologics license application, or BLA, for review.
Capricor Therapeutics Q4 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline progress toward a potential U.S. approval of deramiocel for Duchenne muscular dystrophy (DMD), highlight additional HOPE-3 clinical data presented at a medical meeting, and re